Is Bio-Techne Stock Underperforming the Dow?

Company Overview - Bio-Techne Corporation (TECH) is headquartered in Minneapolis, Minnesota, and specializes in developing, manufacturing, and selling life science reagents, instruments, and services for research, diagnostics, and bioprocessing markets, with a market cap of $8.3 billion [1] - The company focuses on proteins, cytokines, growth factors, immunoassays, and small molecules, positioning itself as a significant player in the biotechnology industry [1] Market Position - TECH is classified as a mid-cap stock, with a market cap exceeding $2 billion, highlighting its size, influence, and dominance within the biotechnology sector [2] - The company is committed to innovation, strategic acquisitions, and has a global presence, which positions it for continued success and growth opportunities both domestically and internationally [2] Stock Performance - Despite its strengths, TECH's stock has decreased by 34.5% from its 52-week high of $80.80, reached on November 6, 2024 [3] - Over the past three months, TECH stock gained 7.3%, underperforming the Dow Jones Industrials Average, which gained 8.7% during the same period [3] - Year-to-date, shares of TECH have dipped 26.5%, and over the past 52 weeks, they have fallen 31.5%, significantly underperforming the Dow Jones Industrials Average's YTD gains of 8.8% and 9.9% returns over the last year [4] Recent Financial Results - On August 6, TECH reported its Q4 results, with an adjusted EPS of $0.53, surpassing Wall Street expectations of $0.50, and revenue of $317 million, exceeding forecasts of $315.4 million [5] - In comparison, Adaptive Biotechnologies Corporation (ADPT) has shown significant resilience, with YTD gains of 132.4% and 227% returns over the past 52 weeks, indicating a competitive challenge for TECH [5]